1
|
Jandrey EHF, Barnabé GF, Maldaun M, Asprino PF, dos Santos NC, Inoue LT, Rozanski A, Galante PAF, Marie SKN, Oba-Shinjo SM, dos Santos TG, Chammas R, Lancellotti CLP, Furnari FB, Camargo AA, Costa ÉT. A novel program of infiltrative control in astrocytomas: ADAM23 depletion promotes cell invasion by activating γ-secretase complex. Neurooncol Adv 2023; 5:vdad147. [PMID: 38024245 PMCID: PMC10681280 DOI: 10.1093/noajnl/vdad147] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2023] Open
Abstract
Background Infiltration is a life-threatening growth pattern in malignant astrocytomas and a significant cause of therapy resistance. It results in the tumor cell spreading deeply into the surrounding brain tissue, fostering tumor recurrence and making complete surgical resection impossible. We need to thoroughly understand the mechanisms underlying diffuse infiltration to develop effective therapies. Methods We integrated in vitro and in vivo functional assays, RNA sequencing, clinical, and expression information from public data sets to investigate the role of ADAM23 expression coupling astrocytoma's growth and motility. Results ADAM23 downregulation resulted in increased infiltration, reduced tumor growth, and improved overall survival in astrocytomas. Additionally, we show that ADAM23 deficiency induces γ-secretase (GS) complex activity, contributing to the production and deposition of the Amyloid-β and release of NICD. Finally, GS ablation in ADAM23-low astrocytomas induced a significant inhibitory effect on the invasive programs. Conclusions Our findings reveal a role for ADAM23 in regulating the balance between cell proliferation and invasiveness in astrocytoma cells, proposing GS inhibition as a therapeutic option in ADAM23 low-expressing astrocytomas.
Collapse
Affiliation(s)
| | | | - Marcos Maldaun
- Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil
| | | | | | | | - Andrei Rozanski
- Molecular Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil
| | | | | | - Sueli Mieko Oba-Shinjo
- Department of Neurology, Laboratory of Molecular and Cellular Biology, LIM15, FMUSP, São Paulo, Brazil
| | - Tiago Góss dos Santos
- Centro Internacional de Pesquisa, A.C. Camargo Cancer Center, Fundação Antônio Prudente, São Paulo, Brazil
| | - Roger Chammas
- Laboratório de Oncologia Experimental, Centro de Investigação Translacional em Oncologia, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil
| | | | - Frank B Furnari
- Ludwig Institute for Cancer Research (LICR), University of California, San Diego, California, USA
| | | | | |
Collapse
|